Screener
D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001434647-26-000068
| Line item | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Revenue, net | $39,663 | $25,881 | $75,883 | $46,282 |
| Cost of product revenue (excluding $316 and $1,616 in intangible asset amortization for the three months ended June 30, 2026, and 2025, respectively, and $632 and $3,231 in intangible asset amortization for the six months ended June 30, 2026, and 2025, respectively, shown separately below) | (1,525) | (12,379) | (3,422) | (13,724) |
| Intangible asset amortization | (316) | (1,616) | (632) | (3,231) |
| Impairment of intangible assets | — | (58,710) | — | (58,710) |
| Gain on sale of future royalties, intellectual property, and other assets, net | — | — | 43,314 | — |
| Operating expenses: | ||||
| Research and development | (4,486) | (3,433) | (8,878) | (6,691) |
| Selling, general and administrative | (16,559) | (20,782) | (37,342) | (40,327) |
ITEM 1.FINANCIAL STATEMENTS
FAQ
- What is Zevra Therapeutics, Inc.'s D&A?
- Zevra Therapeutics, Inc. (ZVRA) reported D&A of $316K in Q2 2026.
- How has Zevra Therapeutics, Inc.'s D&A changed year-over-year?
- Zevra Therapeutics, Inc.'s D&A decreased by 80.4% year-over-year, from $1.62M to $316K.
- What is the long-term trend for Zevra Therapeutics, Inc.'s D&A?
- Over 4 years (2021 to 2025), Zevra Therapeutics, Inc.'s D&A has grown at a 96.9% compound annual growth rate (CAGR), from $257K to $3.86M.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.
Ask your AI about Zevra Therapeutics, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude